Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma

Investigational New Drugs

Volumn 23, Issue 3, 2005, Pages 253-256

  Millward, Michael J ^a,h   Joshua, Anthony ^a   Kefford, Rick ^b   Aamdal, Steinar ^c   Thomson, Damien ^d   Hersey, Peter ^e   Toner, Guy ^f   Lynch, Kevin ^g  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e ROYAL NEWCASTLE HOSPITAL   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g Novartis Pharma Pty Ltd   (Australia)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Melanoma; PET scanning; Polyamines

Indexed keywords

4 AMIDINO 1 INDANONE 2' AMIDINOHYDRAZONE; ADENOSYLMETHIONINE DECARBOXYLASE; DECARBOXYLASE INHIBITOR; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART FUNCTION; HUMAN; HUMAN TISSUE; LETHARGY; MALE; MELANOMA; METABOLISM; METASTASIS; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR BIOPSY;

ADENOSYLMETHIONINE DECARBOXYLASE; ADULT; AGED; AMIDINES; ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INDANS; KARNOFSKY PERFORMANCE STATUS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 18844441837     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-6734-z     Document Type: Article

References (12)

1. Chapman PB, Einhorn LH, Meyers M, Saxman S, Desto AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM: Phase III multicenter randomised trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9): 2745-2751, 1999
2. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH: Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma. An Eastern Cooperative Group study. J Clin Oncol 16(5): 1743-1751, 1998
3. Eton O, Legha SS, Bedekian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a Phase III randomised trial. J Clin Oncol 20(8): 2045-2052, 2002
4. Warrell RP, Burchenal JH: Methylglyoxal bis(guanylhydrazone) (methyl-GAG): Current status and future prospects. J Clin Oncol 1: 52-65, 1983
5. Regenass U, Mett H, Stanek J, Mueller M, Kramer D, Porter CW: CGP48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Cancer Res 54: 3210-3217, 1994
6. Gutman M, Beltran PJ, Fan D, Delworth MG, Singh RK, Wilson MR, Fidler IJ: Treatment of nude mice with 4-amidinoindan-1-one2′-amidinohydrazone, anew S-adenosylmethionine decarboxylase inhibitor, delays growth and inhibits metastases of human melanoma cells. Melanoma Res 5: 147-154, 1995
7. Eskens FALM, Griem GA, van Zuilen C, Wolff I, Denis LJ, Planting AST, Muskiet FA, Wanders J, Barbet NC, Choi L, Capdeville R, Verweij J, Hanauske A-R, Bruntsch U: Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM486 (CGP48664) in patients with solid tumors. Clin Cancer Res 6: 1736-1743, 2000
8. Paridaens R, Uges DRA, Barbet N, Choi L, Seeghers M, van der Graaf WTA, Groen HJM, Dumwz H, van Buuren I, Muskiet F, Capdeville R, van Oosterom AT, de Vries EGE: A Phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumors. Br J Cancer 83: 594-601, 2000
9. Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG: A Phase I and pharmacodynamic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with advanced solid tumors. Clin Cancer Res 8: 2157-2166, 2002
10. Kramer DL, Mett H, Regenass U, Diegelman P, Porter CW: Stable amplification of the S-adenosylmethionine decarboxylase gene in Chinese hamster ovary cells. J Biol Chem 270: 2124-2132, 1995
11. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs 10: 239-253, 1992
12. Pless M, Belhadj K, Menssen HD, Kern W, Coiffier B, Wolf J, Herrmann R, Thiel E, Bootle D, Sklenar I, Muller C, Choi L, Porter C, Capdeville R, et al.: Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with refractory or relapsed non-Hodgkin's lymphoma: Results from a Phase II study. Clin Cancer Res 10: 1299-1305, 2004